WO2021137256A1 - Polymorphic forms of glecaprevir - Google Patents

Polymorphic forms of glecaprevir Download PDF

Info

Publication number
WO2021137256A1
WO2021137256A1 PCT/IN2021/050001 IN2021050001W WO2021137256A1 WO 2021137256 A1 WO2021137256 A1 WO 2021137256A1 IN 2021050001 W IN2021050001 W IN 2021050001W WO 2021137256 A1 WO2021137256 A1 WO 2021137256A1
Authority
WO
WIPO (PCT)
Prior art keywords
glecaprevir
solvent
crystalline
amorphous
preparation
Prior art date
Application number
PCT/IN2021/050001
Other languages
French (fr)
Inventor
Raja Reddy ANUPATI
Ataharoddin Khaja
Jagadeeshwar Rao
Sureshbabu JAYACHANDRA
Original Assignee
Mylan Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Limited filed Critical Mylan Laboratories Limited
Publication of WO2021137256A1 publication Critical patent/WO2021137256A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Definitions

  • the present disclosure relates to novel crystalline and amorphous forms of Glecaprevir and their preparation process thereof.
  • Glecaprevir is a medication used to treat anti-hepatitis C.
  • Glecaprevir is chemically known as (3 aR,7 S , 1 OS , 12R,21 E,24aR)-7 -tert-butyl-N - ⁇ ( lR,2R)-2(difluoromethyl)- 1 - [( 1 - methylcyclopropane-1 sulfonyl)carbamoyl] cyclopropyl]-20,20-difluoro5,8-dioxo- 2,3,3a,5,6,7,8,ll,12,20,23,24a-dodecahydro-lH,10H-9,12methanocyclopenta [18,19]
  • Crystalline Glecaprevir form I, methanol, dimethanol and trimethanol solvates are disclosed in U.S. Patent No. 9,321,807.
  • the inventors of the present disclosure have developed novel crystalline forms and their preparation thereof.
  • a first aspect of the present invention relates to novel crystalline Glecaprevir form Ml.
  • Another aspect of the present invention relates to crystalline Glecaprevir form Ml, characterized by powder x-ray diffraction pattern having significant peaks at 2Q angle positions 6.78, 8.58, 8.83, 10.75, 13.58, 15.02, 16.04, 17.35, 18.98, 19.19, 22.56 ⁇ 0.2°.
  • Yet in another aspect of the present invention relates to a process for the preparation of crystalline Glecaprevir form Ml, which comprises: a) dissolving Glecaprevir in an alcoholic solvent at 50 °C - 60 °C, b) adding an anti-solvent at same temperature, c) cooling the mixture to 25+5 °C, d) filtering to get wet solid; and e) drying the wet solid in an oven with nitrogen blowing at 55 °C - 75 °C to get crystalline form Ml.
  • Yet in another aspect of the present invention relates to crystalline Glecaprevir form M2, characterized by powder x-ray diffraction pattern having significant peaks at 2Q angle positions 7.29, 9.0, 13.95, 14.66, 15.82, 16.49, 17.97, 18.77, 21.39 + 0.2°.
  • Yet in another aspect of the present invention relates to a process for the preparation of crystalline Glecaprevir form M2, which comprises: a) dissolving Glecaprevir in an alcoholic solvent at 50 °C - 60 °C, b) adding an anti-solvent at same temperature, c) cooling the mixture to 25+5 °C, d) filtering to get wet solid; and e) drying under vacuum oven at 25 °C - 65 °C to get crystalline form M2.
  • Yet in another aspect of the present invention relates to a process for the preparation of amorphous Glecaprevir, which comprises: a) dissolving Glecaprevir in a solvent at 25+5 °C; b) adding anti- solvent at 25+5 °C; c) removing the solvent and isolating the amorphous Glecaprevir.
  • Yet in another aspect of the present invention relates to a process for the preparation of amorphous Glecaprevir, which comprises: a) dissolving Glecaprevir in a solvent at 25+5 °C; b) heating the solution of step a) to 55-60 °C; c) adding anti- solvent at 55-60 °C; d) removing the solvent and isolating the amorphous Glecaprevir.
  • Yet in another aspect of the present invention relates to a process for the preparation of amorphous Glecaprevir, which comprises: a) dissolving Glecaprevir in a solvent; b) removing the solvent and isolating the amorphous Glecaprevir.
  • Figure. 1 is an X-ray powder diffractogram of crystalline Glecaprevir form Ml.
  • Figure. 2 is an X-ray powder diffractogram of crystalline Glecaprevir form M2.
  • Figure. 3 is an X-ray powder diffractogram of amorphous Glecaprevir. DETAILED DESCRIPTION OF THE DISCLOSURE
  • the X-ray diffraction patterns of the crystalline Glecaprevir form Ml and form M2 Figure- 1, 2 and 3 are provided herein were measured on PAN analytical, X'Pert PRO powder diffractometer equipped with goniometer of Q/Q configuration and X'Celerator detector.
  • the Cu- anode X-ray tube is operated at 40kV and 30mA. The experiments were conducted over the 2Q range of 2.0°-50.0°, 0.030° step size and 50 seconds step time.
  • the present invention provides novel crystalline forms Glecaprevir designated as forms Ml and M2 and their preparation process thereof.
  • the present invention provides process for the preparation of amorphous Glecaprevir.
  • the present invention provides crystalline Glecaprevir form Ml characterized by X-ray diffraction pattern shown in Fig. 1.
  • the present invention provides crystalline Glecaprevir form Ml, characterized by powder x-ray diffraction pattern having significant peaks at 2Q angle positions 6.78, 8.58, 8.83, 10.75, 13.58, 15.02, 16.04, 17.35, 18.98, 19.19, 22.56 ⁇ 0.2°.
  • the present invention provides a process for the preparation of crystalline Glecaprevir form Ml, which comprises: a) dissolving Glecaprevir in alcoholic solvent at 50 - 60 °C, b) adding an anti-solvent at same temperature, c) cooling the mixture to 25 ⁇ 5°C, d) filtering to get wet solid; and e) drying the wet solid in an oven with nitrogen blowing at 55 - 75 °C to get crystalline form Ml.
  • Glecaprevir may be dissolved in an alcoholic solvent at 55 ⁇ 5°C and added with an antisolvent such as water at same temperature for a period of 90 to 120 minutes. The solid thus precipitated may be gradually cooled to 25+5 °C for 3 hours, filtered and dried for 15-20 hours at 55 - 75 °C to obtain crystalline form
  • the alcohols include, but are not limited to methanol, ethanol, isopropanol, n-propanol or t-butanol.
  • the solvent is methanol.
  • the present invention provides crystalline Glecaprevir form M2 characterized by X-ray diffraction pattern shown in Fig. 2.
  • the present invention provides crystalline Glecaprevir form M2, characterized by powder x-ray diffraction pattern having significant peaks at 2Q angle positions 7.29, 9.0, 13.95, 14.66, 15.82, 16.49, 17.97, 18.77, 21.39 ⁇ 0.2°.
  • the present invention provides a process for the preparation of crystalline Glecaprevir form M2, which comprises: a) dissolving Glecaprevir in alcoholic solvent at 50 - 60 °C, b) adding an anti-solvent at same temperature, c) cooling the mixture to 25+5 °C, d) filtering to get wet solid; and e) drying under vacuum oven at 25 - 65 °C to get crystalline form M2.
  • Glecaprevir may be dissolved in an alcoholic solvent at 55+5°C and added with an antisolvent such as water at same temperature for a period of 90 to 120 minutes.
  • the solid thus precipitated may be cooled the reaction mixture to 25+5 °C for 3 hours, filtered and dried under vacuum oven for 15 to 20 hours at 25 - 65 °C to get crystalline form M2.
  • the alcohols include, but are not limited to methanol, ethanol, isopropanol, n-propanol or t-butanol.
  • the solvent is methanol.
  • the present invention provides a process for the preparation of amorphous Glecaprevir, which comprises: a) dissolving Glecaprevir in a solvent at 25+5 °C; b) adding anti- solvent at 25+5 °C; c) removing the solvent and isolating the amorphous Glecaprevir.
  • Glecaprevir may be dissolved in a solvent at 25+5 °C and added with an antisolvent such as water. The solid thus precipitated may be filtered and dried to obtain amorphous Glecaprevir.
  • the solvent employed may include organic solvents such as methanol, ethanol or propanol.
  • the solvent is methanol.
  • the present invention provides a process for the preparation of amorphous Glecaprevir, which comprises: a) dissolving Glecaprevir in a solvent at 25+5 °C; b) heating the solution of step a) to 55-60 °C; c) adding anti- solvent at 55-60 °C; and d) removing the solvent and isolating the amorphous Glecaprevir.
  • Glecaprevir may be dissolved in a solvent at room temperature and the resulting solution may be heated to 55-60 °C followed by addition of water as an antisolvent at 55-60 °C for 15 to 20 minutes. The solid thus precipitated may filtered and dried to obtain amorphous Glecaprevir.
  • the solvent employed may include, organic solvents such as methanol, ethanol or propanol.
  • the solvent is methanol.
  • the present invention provides a process for the preparation of amorphous Glecaprevir, which comprises: a) dissolving Glecaprevir in a solvent; and b) removing the solvent and isolating the amorphous Glecaprevir.
  • Glecaprevir may be dissolved in a solvent at 25+5 °C followed by removal of the solvent using conventional techniques to get amorphous Glecaprevir.
  • the solvent employed may include organic solvents such as such as methanol, ethanol, propanol dichloromethane, ethyl acetate, acetonitrile or mixtures thereof.
  • the solvent is dichloromethane.
  • removing of solvent may be carried by decantation, filtration by gravity or suction, centrifugation, slow evaporation, distillation, lyophilization, agitated thin film dryer (ATFD) and spray drying.
  • the solvent is removed by distillation.
  • Glecaprevir is prepared by following the method shown in scheme 1.
  • reaction mixture quenched with water (20mL) and then heated to 45-50 °C.
  • a solution of acetic acid (5mL) and water (90mL) were added to the reaction mixture at 45-50 °C, seed crystals of crystalline form Ml were added and maintained for 1 hour at 45-50 °C, water (150mL) was added slowly to the reaction mixture for 90-120 minutes at same temperature.
  • Reaction mixture was cooled to 25+5 °C and stirred for 5-6 hours to get a precipitation. Filtered the obtained solid and washed the compound with water (20mL) to get wet solid.
  • the wet compound was dissolved in methanol (400mL) at 55+5 °C, water (200mL) was added to the reaction mixture at same temperature and stirred for 90-120 minutes to get precipitation. Reaction mixture gradually cooled to 25+5 °C for 3 hours and maintained stirring for 60-90 minutes. The obtained solid was filtered and washed with water (20mL). Compound dried in oven with nitrogen blowing for 15 hours at 65 °C to get crystalline form Ml.
  • the wet compound was dissolved in methanol (1900mL) at 55+5 °C and stirred for, 30 minutes. Reaction mixture was filtered on micron filter. To the filtrate, water (lOOOmL) was added slowly at same temperature for 30-45 minutes and reaction mixture was gradually cooled to 27+5 °C for 3 to 4 hours and maintained the stirring for 90-120 minutes. The obtained solid was filtered and washed with water (2xl000mL) to get wet compound as crystalline form Ml. Wet compound was dried under vacuum at 60+5 °C for 7-9 hours to get crystalline form M2.
  • Glecaprevir (5.0g) was dissolved in methanol (60 mL) at 25+5 °C and water (60mL) was added slowly over 15minutes at 20-25 °C and reaction mixture was stirred for 60minutes. Filtered the obtained solid and washed with water, dried the wet compound under vacuum at 50°C for 5 hours to get amorphous product.
  • Glecaprevir (5g) was dissolved in dichloromethane (100 mL) at 25+5 °C. The contents were distilled out under vacuum at 40°C. The distilled product was dried in rotavapor for 60 minutes to obtain amorphous solid.
  • Glecaprevir (5g) was dissolved in methanol (lOOmL) at 60°C. The resulting clear solution was filtered at 60 °C to remove undissolved particulate and then cooled to 25-30 °C, clear solution was subjected to spray drying in a laboratory spray dryer with feed rate of the solution 5mL/min and inlet temperature at 70°C. The resulting product was identified as amorphous form of Glecaprevir.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present disclosure relates to novel crystalline and amorphous forms of Glecaprevir and their preparation thereof.

Description

POLYMORPHIC FORMS OF GLECAPREVIR
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to the filing dates of Indian provisional Application No. IN202041000312, filed on January 03, 2020 & Indian provisional Application No. IN202041003104, filed on January 23, 2020; each of the preceding are hereby incorporated by reference in their entirety.
FIELD OF THE DISCLOUSRE
The present disclosure relates to novel crystalline and amorphous forms of Glecaprevir and their preparation process thereof.
DESCRIPTION OF THE RELATED ART
Glecaprevir is a medication used to treat anti-hepatitis C. Glecaprevir is chemically known as (3 aR,7 S , 1 OS , 12R,21 E,24aR)-7 -tert-butyl-N - { ( lR,2R)-2(difluoromethyl)- 1 - [( 1 - methylcyclopropane-1 sulfonyl)carbamoyl] cyclopropyl]-20,20-difluoro5,8-dioxo- 2,3,3a,5,6,7,8,ll,12,20,23,24a-dodecahydro-lH,10H-9,12methanocyclopenta [18,19]
[1,10,17,3,6] trioxadiazacyclononadecino [ll,12-b]quinoxaline-10carboxamide hydrate of formula I.
Figure imgf000002_0001
Formula I
Glecaprevir and its preparation is described in U.S. Patent No. 8,648,037.
Crystalline Glecaprevir form I, methanol, dimethanol and trimethanol solvates are disclosed in U.S. Patent No. 9,321,807. The inventors of the present disclosure have developed novel crystalline forms and their preparation thereof.
SUMMARY OF THE DISCLOSURE
A first aspect of the present invention relates to novel crystalline Glecaprevir form Ml.
Another aspect of the present invention relates to crystalline Glecaprevir form Ml, characterized by powder x-ray diffraction pattern having significant peaks at 2Q angle positions 6.78, 8.58, 8.83, 10.75, 13.58, 15.02, 16.04, 17.35, 18.98, 19.19, 22.56 ± 0.2°.
Yet in another aspect of the present invention relates to a process for the preparation of crystalline Glecaprevir form Ml, which comprises: a) dissolving Glecaprevir in an alcoholic solvent at 50 °C - 60 °C, b) adding an anti-solvent at same temperature, c) cooling the mixture to 25+5 °C, d) filtering to get wet solid; and e) drying the wet solid in an oven with nitrogen blowing at 55 °C - 75 °C to get crystalline form Ml.
Yet in another aspect of the present invention relates to novel crystalline Glecaprevir form M2.
Yet in another aspect of the present invention relates to crystalline Glecaprevir form M2, characterized by powder x-ray diffraction pattern having significant peaks at 2Q angle positions 7.29, 9.0, 13.95, 14.66, 15.82, 16.49, 17.97, 18.77, 21.39 + 0.2°.
Yet in another aspect of the present invention relates to a process for the preparation of crystalline Glecaprevir form M2, which comprises: a) dissolving Glecaprevir in an alcoholic solvent at 50 °C - 60 °C, b) adding an anti-solvent at same temperature, c) cooling the mixture to 25+5 °C, d) filtering to get wet solid; and e) drying under vacuum oven at 25 °C - 65 °C to get crystalline form M2. Yet in another aspect of the present invention relates to a process for the preparation of amorphous Glecaprevir, which comprises: a) dissolving Glecaprevir in a solvent at 25+5 °C; b) adding anti- solvent at 25+5 °C; c) removing the solvent and isolating the amorphous Glecaprevir.
Yet in another aspect of the present invention relates to a process for the preparation of amorphous Glecaprevir, which comprises: a) dissolving Glecaprevir in a solvent at 25+5 °C; b) heating the solution of step a) to 55-60 °C; c) adding anti- solvent at 55-60 °C; d) removing the solvent and isolating the amorphous Glecaprevir.
Yet in another aspect of the present invention relates to a process for the preparation of amorphous Glecaprevir, which comprises: a) dissolving Glecaprevir in a solvent; b) removing the solvent and isolating the amorphous Glecaprevir.
BRIEF DESCRIPTION OF THE FIGURES
Further aspects of the present disclosure together with additional features contributing thereto and advantages accruing there from will be apparent from the following description of embodiments of the disclosure which are shown in the accompanying drawing figures wherein:
Figure. 1 is an X-ray powder diffractogram of crystalline Glecaprevir form Ml. Figure. 2 is an X-ray powder diffractogram of crystalline Glecaprevir form M2. Figure. 3 is an X-ray powder diffractogram of amorphous Glecaprevir. DETAILED DESCRIPTION OF THE DISCLOSURE
It is to be understood that the description of the present invention has been simplified to illustrate elements that are relevant for a clear understanding of the invention, while eliminating, for purposes of clarity, other elements that may be well known.
The X-ray diffraction patterns of the crystalline Glecaprevir form Ml and form M2 Figure- 1, 2 and 3 are provided herein were measured on PAN analytical, X'Pert PRO powder diffractometer equipped with goniometer of Q/Q configuration and X'Celerator detector. The Cu- anode X-ray tube is operated at 40kV and 30mA. The experiments were conducted over the 2Q range of 2.0°-50.0°, 0.030° step size and 50 seconds step time.
The present invention provides novel crystalline forms Glecaprevir designated as forms Ml and M2 and their preparation process thereof.
In another embodiment, the present invention provides process for the preparation of amorphous Glecaprevir.
Yet in another embodiment, the present invention provides crystalline Glecaprevir form Ml characterized by X-ray diffraction pattern shown in Fig. 1.
Yet in another embodiment, the present invention provides crystalline Glecaprevir form Ml, characterized by powder x-ray diffraction pattern having significant peaks at 2Q angle positions 6.78, 8.58, 8.83, 10.75, 13.58, 15.02, 16.04, 17.35, 18.98, 19.19, 22.56 ± 0.2°.
Yet in another embodiment, the present invention provides a process for the preparation of crystalline Glecaprevir form Ml, which comprises: a) dissolving Glecaprevir in alcoholic solvent at 50 - 60 °C, b) adding an anti-solvent at same temperature, c) cooling the mixture to 25±5°C, d) filtering to get wet solid; and e) drying the wet solid in an oven with nitrogen blowing at 55 - 75 °C to get crystalline form Ml. Within the context of the present invention, Glecaprevir may be dissolved in an alcoholic solvent at 55±5°C and added with an antisolvent such as water at same temperature for a period of 90 to 120 minutes. The solid thus precipitated may be gradually cooled to 25+5 °C for 3 hours, filtered and dried for 15-20 hours at 55 - 75 °C to obtain crystalline form
Ml.
Within the context of this embodiment of the present invention, the alcohols include, but are not limited to methanol, ethanol, isopropanol, n-propanol or t-butanol. In particular embodiment of the present invention, the solvent is methanol.
Yet in another embodiment, the present invention provides crystalline Glecaprevir form M2 characterized by X-ray diffraction pattern shown in Fig. 2.
Yet in another embodiment, the present invention provides crystalline Glecaprevir form M2, characterized by powder x-ray diffraction pattern having significant peaks at 2Q angle positions 7.29, 9.0, 13.95, 14.66, 15.82, 16.49, 17.97, 18.77, 21.39 ± 0.2°.
Yet in another embodiment, the present invention provides a process for the preparation of crystalline Glecaprevir form M2, which comprises: a) dissolving Glecaprevir in alcoholic solvent at 50 - 60 °C, b) adding an anti-solvent at same temperature, c) cooling the mixture to 25+5 °C, d) filtering to get wet solid; and e) drying under vacuum oven at 25 - 65 °C to get crystalline form M2.
Within the context of the present invention, Glecaprevir may be dissolved in an alcoholic solvent at 55+5°C and added with an antisolvent such as water at same temperature for a period of 90 to 120 minutes. The solid thus precipitated may be cooled the reaction mixture to 25+5 °C for 3 hours, filtered and dried under vacuum oven for 15 to 20 hours at 25 - 65 °C to get crystalline form M2.
Within the context of this embodiment of the present invention, the alcohols include, but are not limited to methanol, ethanol, isopropanol, n-propanol or t-butanol. In particular embodiment of the present invention, the solvent is methanol. Yet in another embodiment, the present invention provides a process for the preparation of amorphous Glecaprevir, which comprises: a) dissolving Glecaprevir in a solvent at 25+5 °C; b) adding anti- solvent at 25+5 °C; c) removing the solvent and isolating the amorphous Glecaprevir.
Within the context of the present invention, Glecaprevir may be dissolved in a solvent at 25+5 °C and added with an antisolvent such as water. The solid thus precipitated may be filtered and dried to obtain amorphous Glecaprevir.
Within the context of this embodiment of the present invention, the solvent employed may include organic solvents such as methanol, ethanol or propanol. In particular embodiment of the present invention, the solvent is methanol.
Yet in another embodiment, the present invention provides a process for the preparation of amorphous Glecaprevir, which comprises: a) dissolving Glecaprevir in a solvent at 25+5 °C; b) heating the solution of step a) to 55-60 °C; c) adding anti- solvent at 55-60 °C; and d) removing the solvent and isolating the amorphous Glecaprevir.
Within the context of the present invention, Glecaprevir may be dissolved in a solvent at room temperature and the resulting solution may be heated to 55-60 °C followed by addition of water as an antisolvent at 55-60 °C for 15 to 20 minutes. The solid thus precipitated may filtered and dried to obtain amorphous Glecaprevir.
Within the context of this embodiment of the present invention, the solvent employed may include, organic solvents such as methanol, ethanol or propanol. In particular embodiment of the present invention, the solvent is methanol.
Yet in another embodiment, the present invention provides a process for the preparation of amorphous Glecaprevir, which comprises: a) dissolving Glecaprevir in a solvent; and b) removing the solvent and isolating the amorphous Glecaprevir. Within the context of the present invention, Glecaprevir may be dissolved in a solvent at 25+5 °C followed by removal of the solvent using conventional techniques to get amorphous Glecaprevir.
Within the context of this embodiment of the present invention, the solvent employed may include organic solvents such as such as methanol, ethanol, propanol dichloromethane, ethyl acetate, acetonitrile or mixtures thereof. In particular embodiment of the present invention, the solvent is dichloromethane.
Within the context of this embodiment of the present invention, removing of solvent may be carried by decantation, filtration by gravity or suction, centrifugation, slow evaporation, distillation, lyophilization, agitated thin film dryer (ATFD) and spray drying. In particular useful embodiment of the present invention, the solvent is removed by distillation.
Within the context of the present invention, Glecaprevir is prepared by following the method shown in scheme 1.
Figure imgf000008_0001
Scheme-1
In view of the above description and the examples below, one of ordinary skill in the art will be able to practice the invention as claimed without undue experimentation. The foregoing will be better understood with reference to the following examples that detail certain procedures for the preparation of molecules, compositions and Formulations according to the present invention. All references made to these examples are for the purposes of illustration. The following examples should not be considered exhaustive, but merely illustrative of only a few of the many aspects and embodiments contemplated by the present disclosure.
EXAMPLES
Example- 1: Preparation of crystalline Glecaprevir form Ml
Compound of formula II (20g) 2-hydroxypyridine N-oxide (5.09g,) l-ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride (EDAC;1.04g) were taken in acetonitrile (80mL) and stirred for 30 minutes at 25±5°C to get clear solution of acid complex. In another flask sulfonamide compound of formula III (11.38g) and triethylamine (7.56g) was taken in acetonitrile (80mL) and stirred at 25+5 °C. Acid complex solution was added slowly to the sulfonamide mixture for 15 minutes at 25+5 °C and stirred for 15 hours. After completion of reaction, mixture quenched with water (20mL) and then heated to 45-50 °C. A solution of acetic acid (5mL) and water (90mL) were added to the reaction mixture at 45-50 °C, seed crystals of crystalline form Ml were added and maintained for 1 hour at 45-50 °C, water (150mL) was added slowly to the reaction mixture for 90-120 minutes at same temperature. Reaction mixture was cooled to 25+5 °C and stirred for 5-6 hours to get a precipitation. Filtered the obtained solid and washed the compound with water (20mL) to get wet solid.
The wet compound was dissolved in methanol (400mL) at 55+5 °C, water (200mL) was added to the reaction mixture at same temperature and stirred for 90-120 minutes to get precipitation. Reaction mixture gradually cooled to 25+5 °C for 3 hours and maintained stirring for 60-90 minutes. The obtained solid was filtered and washed with water (20mL). Compound dried in oven with nitrogen blowing for 15 hours at 65 °C to get crystalline form Ml.
Example-2: Preparation of crystalline Glecaprevir form M2
Compound of formula II (lOOg) 2-hydroxypyridine N-oxide (25.48g,) l-ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride (EDAC; 42.33g) were taken in acetonitrile (900mL) and stirred for 30-60 minutes at 25+5°C to get clear solution of acid complex. Sulfonamide compound of formula III (56.90g) was added to the above clear solution. Triethylamine (38.68g) was slowly added to the above reaction mixture and stirred at 25+5 °C for 15 to 20 hours. After completion of reaction, mixture quenched with water (lOOmL) and then heated to 45-50 °C. A solution of acetic acid (5mL) and water (90mL) were added to the reaction mixture at 45-50 °C, seed crystals of crystalline form Ml were added and maintained for 1-2 hours at 45-50 °C, water (750mL) was added slowly to the reaction mixture for 60-90 minutes at same temperature. Reaction mixture was cooled to 25+5 °C and stirred for 10-11 hours to get a precipitation. Filtered the obtained solid and washed the compound with water (20mL) to get wet solid.
The wet compound was dissolved in methanol (1900mL) at 55+5 °C and stirred for, 30 minutes. Reaction mixture was filtered on micron filter. To the filtrate, water (lOOOmL) was added slowly at same temperature for 30-45 minutes and reaction mixture was gradually cooled to 27+5 °C for 3 to 4 hours and maintained the stirring for 90-120 minutes. The obtained solid was filtered and washed with water (2xl000mL) to get wet compound as crystalline form Ml. Wet compound was dried under vacuum at 60+5 °C for 7-9 hours to get crystalline form M2.
Example-3: Preparation of crystalline Glecaprevir form M2
The Glecaprevir wet compound dissolved in methanol (400mL) at 55+5 °C then water (200mL) was added to the reaction mixture at same temperature and stirred for 90-120 minutes to get precipitation. Reaction mixture gradually cooled to 25+5 °C for 3 hours, reaction maintained for 60-90 minutes then filtered the obtained solid and washed the wet compound with water (20mL). Wet compound dried in hot air oven at 50 °C for 15 hours to get crystalline form M2.
Example-4: Preparation of crystalline Glecaprevir form M2
The Glecaprevir wet compound dissolved in methanol (400mL) at 55+5 °C then water (200mL) was added to the reaction mixture at same temperature and stirred for 90-120 minutes to get precipitation. Reaction mixture gradually cooled to 25+5 °C for 3 hours, reaction maintained for 60-90 minutes then filtered the obtained solid and washed the wet compound with water (20mL). Wet compound dried under vacuum oven for 15 hours at 25 °C to get crystalline form M2. Example-5: Preparation of crystalline Glecaprevir form M2
The Glecaprevir wet compound dissolved in methanol (400mL) at 55+5 °C then water (200mL) was added to the reaction mixture at same temperature and stirred for 90-120 minutes to get precipitation. Reaction mixture gradually cooled to 25+5 °C for 3 hours, reaction maintained for 60-90 minutes then filtered the obtained solid and washed the wet compound with water (20mL). Wet compound dried in vacuum oven for 15 hours at 45 °C to get crystalline form M2.
Example-6: Preparation of crystalline Glecaprevir form M2
The Glecaprevir wet compound dissolved in methanol (400mL) at 55+5 °C then water (200mL) was added to the reaction mixture at same temperature and stirred for 90-120 minutes to get precipitation. Reaction mixture gradually cooled to 25+5 °C for 3 hours, reaction maintained for 60-90 minutes then filtered the obtained solid and washed the wet compound with water (20mL). Wet compound dried in vacuum oven for 15 hours at 65 °C to get crystalline form M2.
Example-7: Preparation of amorphous Glecaprevir
Compound of formula II (2.0g), 2-Hydroxypyridine N-oxide (0.5g) l-ethyl-3-(3- dimethylaminopropyl) carbodiimide (EDAC;1.04g) were taken in acetonitrile(8mL) and stirred for 30 minutes at 25+5 °C to get clear solution of acid complex. In another flask carboxamide compound of formula III (1.2g) and triethylamine (0.85g) was taken in acetonitrile (8mL) and stirred at 25+5 °C. Acid complex solution was added slowly to the carboxamide mixture for 15minutes at 25+5 °C and stirred for 15 hours. After completion of reaction, water was added slowly to the reaction mixture followed by aqueous acetic acid solution. The reaction mixture was extracted with ethyl acetate and organic layer was concentrated under vacuum to obtain foamy solid.
Methanol (24mL) was added to obtained foamy solid at 25+5 °C and heated to 55-60 °C then water (24mL) was slowly added to the reaction mixture at same temperature and stirred for 2 hours. The obtained solid was filtered and washed with water. Wet compound was dried under vacuum to get amorphous Glecaprevir of formula I.
Yield: 2.0 g Example-8: Preparation of amorphous Glecaprevir
Glecaprevir (5.0g) was dissolved in methanol (60 mL) at 25+5 °C and water (60mL) was added slowly over 15minutes at 20-25 °C and reaction mixture was stirred for 60minutes. Filtered the obtained solid and washed with water, dried the wet compound under vacuum at 50°C for 5 hours to get amorphous product.
Yield: 2.0 g
Example-9: Preparation of amorphous Glecaprevir
Glecaprevir (5g) was dissolved in dichloromethane (100 mL) at 25+5 °C. The contents were distilled out under vacuum at 40°C. The distilled product was dried in rotavapor for 60 minutes to obtain amorphous solid.
Yield: 4.8g
Example-10: Preparation of amorphous Glecaprevir
Crude Glecaprevir (5g) was purified by column chromatography with eluent of ethyl acetate in n-hexane (1:1) and distilled of pure fraction under vacuum at 50-55°C in rotavapor to get amorphous solid.
Yield: 4.2g
Example-11: Preparation of amorphous Glecaprevir
Glecaprevir (5g) was dissolved in methanol (lOOmL) at 60°C. The resulting clear solution was filtered at 60 °C to remove undissolved particulate and then cooled to 25-30 °C, clear solution was subjected to spray drying in a laboratory spray dryer with feed rate of the solution 5mL/min and inlet temperature at 70°C. The resulting product was identified as amorphous form of Glecaprevir.
Yield: 4.0 g

Claims

We claim:
1. Crystalline Glecaprevir form M2.
2. The crystalline Glecaprevir form M2 as claimed in claim 1, is characterized by powder x-ray diffraction pattern having significant peaks at 2Q angle positions 7.29, 9.0, 13.95, 14.66, 15.82, 16.49, 17.97, 18.77, 21.39 ± 0.2°.
3. The crystalline Glecaprevir form M2 as claimed in claim 1, is prepared comprising the steps of a) dissolving Glecaprevir in an alcoholic solvent at 50 °C - 60 °C, b) adding an anti- solvent at same temperature, c) cooling the mixture to 25+5 °C, d) filtering to get wet solid; and e) drying under vacuum oven at 25 °C - 65 °C to get crystalline form M2.
4. Crystalline Glecaprevir form Ml.
5. The crystalline Glecaprevir form Ml as claimed in claim 4, is characterized by powder x-ray diffraction pattern having significant peaks at 2Q angle positions 6.78, 8.58, 8.83, 10.75, 13.58, 15.02, 16.04, 17.35, 18.98, 19.19, 22.56 + 0.2°.
6. The crystalline Glecaprevir form Ml as claimed in claim 4, is prepared comprising the steps of a) dissolving Glecaprevir in an alcoholic solvent at 50 °C - 60 °C, b) adding an anti- solvent at same temperature, c) cooling the mixture to 25+5 °C, d) filtering to get wet solid; and e) drying the wet solid in an oven with nitrogen blowing at 55 °C - 75 °C to get crystalline form Ml.
7. A process for the preparation of amorphous Glecaprevir comprising the steps of: a) dissolving Glecaprevir in a solvent at 25+5 °C; b) adding anti-solvent at 25+5 °C; c) removing the solvent and isolating the amorphous Glecaprevir.
8. A process for the preparation of amorphous Glecaprevir comprising the steps of: a) dissolving Glecaprevir in a solvent at 25+5 °C; b) heating the solution of step a) to 55-60 °C; c) adding anti-solvent at 55-60 °C; d) removing the solvent and isolating the amorphous Glecaprevir.
9. A process for the preparation of amorphous Glecaprevir comprising the steps of: a) dissolving Glecaprevir in a solvent; b) removing the solvent and isolating the amorphous Glecaprevir.
10. The process according to any of the preceding claims, wherein the alcoholic solvent is selected from methanol, ethanol, IPA and solvent is dichloromethane, methanol or mixtures thereof.
PCT/IN2021/050001 2020-01-03 2021-01-01 Polymorphic forms of glecaprevir WO2021137256A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN202041000312 2020-01-03
IN202041000312 2020-01-03
IN202041003104 2020-01-23
IN202041003104 2020-01-23

Publications (1)

Publication Number Publication Date
WO2021137256A1 true WO2021137256A1 (en) 2021-07-08

Family

ID=74550718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2021/050001 WO2021137256A1 (en) 2020-01-03 2021-01-01 Polymorphic forms of glecaprevir

Country Status (1)

Country Link
WO (1) WO2021137256A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8648037B2 (en) 2010-09-21 2014-02-11 Enanta Pharmaceuticals, Inc. Macrocyclic proline derived HCV serine protease inhibitors
US9321807B2 (en) 2014-06-06 2016-04-26 Abbvie Inc. Crystal forms

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8648037B2 (en) 2010-09-21 2014-02-11 Enanta Pharmaceuticals, Inc. Macrocyclic proline derived HCV serine protease inhibitors
US9321807B2 (en) 2014-06-06 2016-04-26 Abbvie Inc. Crystal forms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MINO R CAIRA ED - MONTCHAMP JEAN-LUC: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY; [TOPICS IN CURRENT CHEMISTRY], SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP008166276, ISSN: 0340-1022, [retrieved on 19990226], DOI: 10.1007/3-540-69178-2_5 *

Similar Documents

Publication Publication Date Title
CA2722496C (en) Crystalline minocycline base and processes for its preparation
US20090192200A1 (en) Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
US20090298947A1 (en) Polymorphic and amorphous forms of lacosamide and amorphous compositions
CN111511371A (en) Polymorphs and co-crystals of rosuvastatin
WO2017046815A1 (en) Polymorphs of ixazomib citrate and processes for the preparation thereof
WO2011024192A2 (en) Novel polymorphs of raltegravir
US20090281315A1 (en) Forms of lapatinib ditosylate and processes for preparation thereof
EP1945636A2 (en) Polymorphs of solifenacin intermediate
WO2005009955A1 (en) Ezetimibe polymorphs
WO2021137256A1 (en) Polymorphic forms of glecaprevir
WO2011153221A1 (en) Solid state forms of ixabepilone
US10259790B2 (en) Polymorphic forms of pitavastatin sodium
WO2008010087A2 (en) Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
US20240082248A1 (en) Process for preparation of mavacamten and solid state forms thereof
WO2014195977A2 (en) Novel polymorphs of vismodegib
US10300044B2 (en) Polymorphic forms of methyl((1S)-1-(((2S)-2-(5-(4′-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate and salts thereof
RU2669785C2 (en) Polymorphic form of sodium hyodeoxycholate (nahdc) and preparation process thereof
AU2012354150A1 (en) Amorphous vilazodone hydrochloride, a process for its preparation and pharmaceutical compositions thereof
WO2017115324A1 (en) Solid forms of obeticholic acid and processes thereof
WO2020217190A1 (en) Process for the purification of roxadustat
CN106432253B (en) A kind of Wei Patawei novel crystal forms and preparation method thereof
WO2019207498A1 (en) Solid forms of 8-fluoro-2-{4-[(methylamino)methyl] phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd] indol-6-one ((1s,4r)-7,7dimethyl-2-oxobicyclo [2.2.1] hept-1-yl) methanesulfonic acid salt (rucaparib camsylate) and the prerparation thereof
KR100920314B1 (en) Novel salt of Montelukast and the preparing method thereof
WO2017098532A1 (en) Crystalline and amorphous forms of carfilzomib
CN111217782A (en) beraprost-314D monohydrate crystals and process for producing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21703333

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21703333

Country of ref document: EP

Kind code of ref document: A1